MDxHealth (NASDAQ:MDXH) Cut to “Hold” at Lake Street Capital

Lake Street Capital downgraded shares of MDxHealth (NASDAQ:MDXH) from a buy rating to a hold rating in a research note released on Friday morning, Marketbeat Ratings reports. They currently have $0.50 price objective on the stock.

Several other research firms also recently weighed in on MDXH. Craig Hallum downgraded shares of MDxHealth from a “buy” rating to a “hold” rating in a research report on Friday. BTIG Research cut their target price on shares of MDxHealth from $4.00 to $2.00 and set a “buy” rating on the stock in a research note on Friday, August 21st. Wall Street Zen raised shares of MDxHealth to a “sell” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings downgraded MDxHealth from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $1.33.

MDxHealth Price Performance

MDXH opened at $0.21 on Friday. The stock has a market capitalization of $10.23 million, a PE ratio of -0.29 and a beta of 1.68. The firm’s fifty day moving average price is $0.64 and its 200 day moving average price is $0.91. MDxHealth has a 12-month low of $0.19 and a 12-month high of $5.33.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. The company had revenue of $27.21 million for the quarter, compared to the consensus estimate of $26.14 million. On average, equities research analysts forecast that MDxHealth will post -0.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

Several institutional investors and hedge funds have recently made changes to their positions in MDXH. Squarepoint Ops LLC acquired a new stake in shares of MDxHealth during the 2nd quarter valued at approximately $82,000. Perkins Capital Management Inc. lifted its stake in MDxHealth by 7.1% during the first quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock worth $3,396,000 after purchasing an additional 97,500 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in MDxHealth by 21.8% in the first quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock worth $701,000 after purchasing an additional 54,600 shares during the period. Finally, Bank of America Corp DE boosted its holdings in MDxHealth by 213.9% in the first quarter. Bank of America Corp DE now owns 43,492 shares of the company’s stock worth $100,000 after purchasing an additional 29,638 shares during the period.

MDxHealth Company Profile

MDxHealth is a precision diagnostics company focused on improving the detection, diagnosis and management of cancer. The company develops and commercializes molecular and genomic tests designed to help physicians assess cancer risk, guide treatment decisions and monitor patients, with a primary focus on urological cancers.

Its product portfolio includes ConfirmMDx, a tissue-based test intended to help identify men who may have clinically significant prostate cancer after a prior negative biopsy; SelectMDx, a urine-based test that helps assess the likelihood of clinically significant prostate cancer; and ResolveMDx, a molecular test designed to support prostate cancer risk assessment.